New Brunswick, N.J.-based Johnson & Johnson on Monday released a report detailing price increases for its prescription drugs, reports CNBC.
Here are five things to know.
1. The drugmaker first shared plans to release the report in January amid growing scrutiny over high drug prices.
2. The report details the average list and net price increases of J&J's medications. The report does not include figures for individual drugs, however, since discounts given to middlemen like wholesalers, retailers and pharmacy benefit managers are competitive information.
3. Between 2012 and 2016, J&J's list prices have increased by an average of less than 10 percent. Net prices, which account for discounts and rebates, increased on average less than 5 percent each year, according to the report.
4. In 2016, J&J reported an average list price increase of 8.5 percent and an average net price increase of 3.5 percent — lower than the 4.1 percent rate of medical inflation in the U.S. for 2016.
5. The drugmaker said discounts and rebates on its treatments totaled about $11 billion in the U.S. last year, representing a discount rate of 35 percent off the list price, according to the report.
More articles on supply chain:
FDA approves generic Tamiflu
Sanofi, Lonza to build $285M biologics facility
4 statistics on 2017 pharma price hikes